Pharmos (PARS) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Pharmos (PARS)

PARS 2.700

+13.6%

Jan 21 4:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: gfp927z	12/3/2004 1:15:53 AM
	Read Replies (1) of 1386

Clark, Concerning your point about the seemingly low 26% GOSE 7-8 grouping in the Phase 3 (the outcome data after 621 patients), another explanation might involve the fact that GOSE is a finer scale than the earlier GOS scale, with 8 categories vrs 5 categories. Some of the patients who in the Phase 2 would have been lumped together on the GOS scale as GOS 5 ("good recovery"), were perhaps scored as GOSE 6 ("upper mod disabled") on the more precise GOSE scale. Anyway, just a thought. This overlap between GOSE/GOS categories, along with the enrollment of overall sicker patients in the Phase 3, might explain the apparently "low" 26% figure.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next